"Tissue Regenix further advances US commercialisation strategy through Community Tissue Services partnership
Tissue Regenix (‘TRX’), the British regenerative medical device company, today announces it has signed a processing partnership with Community Tissue Services in the United States.
Community Tissue Services is one of the largest tissue banks in the United States, distributing over 230,000 grafts for transplant annually. Under the terms of the partnership, Community Tissue Services will use Tissue Regenix’s patented dCELL® technology to produce human biological scaffolds initially for use in acute and chronic wound care but ultimately to expand to cover other areas of clinical need.
Tissue Regenix’s dCELL® dermis works by taking human donor skin and removing the DNA and cells, using the patented dCELL® process to leave a dermis matrix that can be placed over the wound to aid natural healing by attracting the patient’s own cells to the wound area.
Recently completed trials in the UK with NHS Blood and Transplant (‘NHSBT’) have shown that patients who have had tough chronic wounds for 4 ½ years who were treated with Tissue Regenix dCELL® Dermis have seen an 87% reduction in the size of all wounds, while 60% of patients were completely healed with virtually no recurrences.
In the US, chronic wounds affect 6.5 million patients at a cost of care greater than $25bn. The partnership with Community Tissue Services will allow Tissue Regenix to create dCELL® Dermis products in order to target the existing $1.4bn market for wound healing devices & equipment, which is anticipated to reach $1.5bn by 2016. icon We are delighted to announce this partnership with Community Tissue Services. This agreement will allow Tissue Regenix to advance our development and commercialisation of dCELL® Dermis. We are excited to begin providing our dCELL® technology to physicians and clinicians who treat patients suffering from chronic and acute wounds. Many people who suffer with chronic wounds often do so for many years. Conventional treatments may not be as effective and statistics show that some patients are readmitted to the hospital due to infection or other complications associated with the wound failing to heal properly.
Recent studies show that dCELL® dermis is easy to apply and may require less time for the busy physician compared to other dermis products used today. The dCELL® dermis does not require storage on dry ice and does not require re-hydration or special set up before application. In the recent study conducted at the University Hospital of South Manchester, dCELL® dermis was successfully applied to patients in as little as 30-40 minutes.
Greg Bila, President, Tissue Regenix Wound Care Inc.
We are extremely excited to partner with Tissue Regenix. Tissue Regenix’s dCELL® Dermis will offer the latest technology in wound care management to patients suffering from acute and chronic wounds. Dr. David M. Smith, Chief Executive Officer of Community Tissue Services
[Antony Odell, Managing Director of Tissue Regenix ] Tissue Regenix’s partnership with Community Tissue Services will enable us to bring the benefit of dCELL® technology to address a wide range of patient needs. This is an important step in our global commercialisation strategy and is a first step in bringing the benefits of dCELL® Technology to the US. We remain on course for a US commercial launch of dCELL® Dermis in the first half of 2014."
This paragraph shows that the technology isn`t any better than what CZD are doing with the VAC dressing trial which showed >80% reduction in wound size in patients undergoing Dr Greenwoods trial(see the slide show presented to American Burns Assoc)
Recently completed trials in the UK with NHS Blood and Transplant (‘NHSBT’) have shown that patients who have had tough chronic wounds for 4 ½ years who were treated with Tissue Regenix dCELL® Dermis have seen an 87% reduction in the size of all wounds, while 60% of patients were completely healed with virtually no recurrences.
The following is from a trial conducted by Regenix that seems pretty much the same as Polynovos` BTM trial nearing completion with "excellent results" according to the recent update.
Tissue Regenix Group PLC : Results of dCELL Dermis trial 05/02/2013| 02:37am US/Eastern Recommend: 0
?
Tissue Regenix Group plc
Results of dCELL®Dermis trial in chronic leg ulcers
NHSBT and Tissue Regenix collaborate to develop new treatment
dCELL® Dermis available from NHSBT Tissue Services from Summer 2013
YORK, 2nd May 2013 - Tissue Regenix Group Plc ('TRX'), the regenerative medical device company, announces that more than half of patients involved in the first trial of a new treatment for chronic leg ulcers have had their wounds completely healed.
This trial of a new clinical product, produced by NHS Blood and Transplant (NHSBT) Tissue Services, used a novel graft prepared using Tissue Regenix' dCELL® technology from skin donated by deceased tissue donors and processed to remove all the donor cells.
This new therapy involves a graft, known as dCELL® Human Dermis, which is not rejected by the patients' immune system. It maintains the essential structure of normal skin and serves as an ideal scaffold for the patients' cells to migrate into and regenerate living, functional skin tissue.
dCELL® dermis works by taking human donor skin and removing the DNA and cells, using Tissue Regenix' patented dCELL® process, to leave a dermis matrix that can be placed over the wound to aid natural healing.
Lower limb ulcers, which are often secondary to other conditions such as poor circulation and diabetes, are a common age-related condition which is increasing in frequency with an aging and increasingly unfit population.
Professor John Kearney, NHS Blood and Transplant Tissue Services
Head of Research and Development said:
"All of these wounds are painful, debilitating and reduce the patient's quality of life. In some cases they can lead to the patient requiring full or partial amputation. The study showed that dCELL® Human Dermis treatment is capable of completely healing chronic leg ulcers in some patients and decreases the size of the wound in others. This evidence offers hope that the treatment will benefit patients in a clinical setting in future.
"Care and treatment of chronic leg ulcers is estimated to consume 1% of the NHS total budget¹. Our research and development of a treatment that can heal these wounds may lead to better use of NHS resources and greatly improve patients' quality of life."
Antony Odell, Managing Director Tissue Regenix, said:"This is a significant development for NHSBT and Tissue Regenix. Tissue Regenix has partnered with NHSBT to develop dermis treatments using our dCELL® technology. This dCELL® Dermis clinical treatment has the potential to help many patients and address the £400 million annual bill that the NHS pays to treat chronic wounds of the lower leg.
"Research firm Kalorama estimates the global market for chronic and acute wound care could be worth $21 billion by 2015 (from $16.8 billion in 2012). The successful trial and development of this NHSBT Dermis treatment is a critical part of our ongoing plans to commercialise treatments developed using our dCELL® technology."
So CZD/Polynovo are ticking all the boxes with a product that is cheaper to produce and doesnt` have to harvested from human cadaver tissue.
It is always better to trial against a product, I would like to see a trial with Regenixs` products to see the outcome. It is also good /advisable to know what/who the others are in the race. I am very happy with CZDs position.
Get em while they are cheap!!
CZD Price at posting:
6.8¢ Sentiment: Buy Disclosure: Held
